Condensed Consolidated Statements Of Cash Flows (Unaudited) (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Cash Flows from Operating Activities
Net income (loss)	$ (4,568)	$ 1,444
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	8,955	8,680
Gain on sale of bioplastics manufacturing business	(1,453)	0
Gain on sale of joint venture interest	0	(4,055)
Gain on sale of assets, net	0	(841)
Share based compensation	970	628
Equity in (earnings) loss of Joint Ventures	962	(164)
Changes in operating assets and liabilities:
Restricted cash	12	7,476
Receivables, net	3,529	(2,490)
Inventory	(342)	(3,423)
Prepaid expenses	(541)	(621)
Refundable income taxes	16	152
Accounts payable	(509)	(8,031)
Accounts payable to affiliate, net	(3,491)	(3,595)
Accrued expenses	1,478	1,311
Change in derivatives	0	(2,492)
Deferred credit	(340)	(448)
Accrued retirement health and life insurance benefits and other noncurrent liabilities	(680)	(826)
Other	6	(158)
Net cash provided by (used by) operating activities	4,004	(7,453)
Cash Flows from Investing Activities
Proceeds from sale of bioplastics manufacturing business	2,797	0
Proceeds from sale of joint venture interest	0	9,103
Proceeds from the disposition of property and equipment	0	3,215
Additions to property and equipment	(3,571)	(7,712)
Investment in and advances to unconsolidated subsidiaries	0	(500)
Net cash provided by (used by) investing activities	(774)	4,106
Cash Flows from Financing Activities
Payments of dividends	(916)	(914)
Payments of Loan Costs	0	(100)
Principal payments on long-term debt	(1,288)	(1,248)
Proceeds from revolving credit facility	83,031	99,239
Payments on revolving credit facility	(84,057)	(94,013)
Net cash provided by (used by) financing activities	(3,230)	2,964
Decrease in cash and cash equivalents	0	(383)
Cash and cash equivalents, beginning of year	0	383
Cash and cash equivalents, end of period	$ 0	$ 0